5-FU (fluorouracil) is a moderately potent chemotherapy drug that has been a cornerstone of cancer treatment for decades. It’s not the most aggressive single agent available, but it carries real side effects, and up to 30% of patients experience severe toxicity. Its strength comes largely from how it’s combined with other drugs, which can more than double its effectiveness.
What 5-FU Does Inside the Body
5-FU belongs to a class of chemotherapy drugs called antimetabolites. Rather than directly poisoning cancer cells the way some chemo drugs do, it works by disguising itself as a building block cells need to copy their DNA. Once inside the cell, it blocks an enzyme essential for DNA production and also gets incorporated into RNA, disrupting the cell’s ability to grow and divide. This makes it effective but also means it affects healthy cells that divide quickly, like those lining the mouth and gut.
Which Cancers It Treats
5-FU is most closely associated with colorectal cancer, where it serves as the backbone of nearly every standard chemotherapy regimen. It’s also used in cancers of the stomach, breast, head and neck, and pancreas. In most of these settings, 5-FU is given alongside other drugs rather than on its own, because its solo performance is moderate. When used alone in advanced colorectal cancer, 5-FU produces a median survival of about 7.7 months. Adding a vitamin compound called leucovorin, which enhances 5-FU’s activity, pushes median survival to roughly 12 months and significantly improves tumor response rates.
How Combination Regimens Increase Its Power
The real potency of 5-FU shows up in combination therapy. Two of the most common regimens for metastatic colon cancer pair 5-FU with either a platinum-based drug (known as FOLFOX) or a different agent that disrupts DNA replication (known as FOLFIRI). These combinations dramatically change the picture.
5-FU with leucovorin alone has a response rate of about 21% to 22%. Adding the platinum drug raises that to 53%, with progression-free survival jumping from 6 months to 9 months. The alternative combination achieves a 39% response rate with 7 months of progression-free survival. Head-to-head trials comparing FOLFOX and FOLFIRI found both regimens performed similarly, with response rates of 54% to 56% and progression-free survival around 8 to 8.5 months. So while 5-FU alone is moderate in strength, it becomes considerably more effective as the foundation of these multi-drug protocols.
Common Side Effects
5-FU’s side effect profile is significant but generally manageable compared to some of the more aggressive chemotherapy drugs. The most frequent problems involve the digestive system. Out of every 100 people receiving 5-FU, more than 20 will experience diarrhea, nausea, vomiting, or mouth sores that can make swallowing difficult. Between 4 and 20 out of 100 will develop infections (particularly when white blood cell counts drop) or anemia that may require blood transfusions.
One distinctive side effect is hand-foot syndrome, a condition where the palms and soles become red, swollen, and painful. In studies of patients receiving 5-FU by continuous infusion, about 77% developed some degree of hand-foot syndrome, though most cases were mild (grade one). This side effect is more common with continuous infusion than with quick injections of the drug.
How the Delivery Method Changes the Experience
5-FU can be given as a quick injection (bolus) or as a slow, continuous drip over hours or days. These two approaches produce noticeably different results. Continuous infusion yields a higher tumor response rate (22% vs. 14%) and a slight improvement in overall survival compared to bolus dosing.
The side effects shift too. Quick injections cause far more blood-related toxicity: 31% of patients develop severe drops in blood cell counts, compared to just 4% with continuous infusion. On the other hand, continuous infusion leads to more hand-foot syndrome (34% vs. 13%). Your oncology team chooses the method based on the specific regimen, the treatment goals, and which side effects are most important to manage in your case.
The DPD Deficiency Risk
One factor that can make 5-FU unexpectedly dangerous is a genetic condition affecting how your body breaks down the drug. An enzyme called DPD is responsible for clearing about 80% of 5-FU from the body. Roughly 0.3% of the population completely lacks this enzyme, and those individuals can experience extreme, potentially fatal toxicity because the drug accumulates instead of being cleared.
Even partial deficiency matters. Overall, up to 30% of patients treated with 5-FU experience severe side effects, and the drug proves fatal in roughly 1% of cases. The severity depends on which genetic variants a person carries. People with two nonfunctional copies of the gene responsible for DPD production face the highest risk. Many cancer centers now offer genetic testing before starting 5-FU to identify patients who need a lower dose or an alternative drug entirely.
How It Compares to Other Chemo Drugs
In the broader landscape of chemotherapy, 5-FU sits in the middle tier of intensity. It’s not in the same category as the most aggressive regimens used for lymphomas or testicular cancer, which tend to cause more profound immune suppression and hair loss. But it’s far from a mild treatment. Its side effects are real and sometimes severe, and the drug demands respect, particularly because of the DPD deficiency issue.
What sets 5-FU apart is its versatility and track record. It has been in use since the 1960s, and oncologists understand its behavior extremely well. It remains the backbone of first-line treatment for one of the most common cancers worldwide. Its “strength” is best understood not as a single number but as a spectrum: modest on its own, substantially more powerful in combination, and potentially overwhelming for the small percentage of patients whose bodies can’t metabolize it properly.